These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 12559642)

  • 1. A model for the interim analysis process: a case study.
    Delgado-Herrera L; Anbar D
    Control Clin Trials; 2003 Feb; 24(1):51-65. PubMed ID: 12559642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Interim analyses].
    Kramar A; Paoletti X
    Bull Cancer; 2007 Nov; 94(11):965-74. PubMed ID: 18055314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DSMB case study: decision making when a similar clinical trial is stopped early.
    Hillman DW; Louis TA
    Control Clin Trials; 2003 Feb; 24(1):85-91. PubMed ID: 12559646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report.
    Korn EL; Freidlin B
    Am J Bioeth; 2011 Mar; 11(3):2-10. PubMed ID: 21400374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review of the reporting of Data Monitoring Committees' roles, interim analysis and early termination in pediatric clinical trials.
    Fernandes RM; van der Lee JH; Offringa M
    BMC Pediatr; 2009 Dec; 9():77. PubMed ID: 20003383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Data monitoring committees: Promoting best practices to address emerging challenges.
    Fleming TR; DeMets DL; Roe MT; Wittes J; Calis KA; Vora AN; Meisel A; Bain RP; Konstam MA; Pencina MJ; Gordon DJ; Mahaffey KW; Hennekens CH; Neaton JD; Pearson GD; Andersson TL; Pfeffer MA; Ellenberg SS
    Clin Trials; 2017 Apr; 14(2):115-123. PubMed ID: 28359194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Independent data monitoring committees: an update and overview.
    Sartor O; Halabi S
    Urol Oncol; 2015 Mar; 33(3):143-8. PubMed ID: 25631301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Data monitoring committees and interim monitoring guidelines.
    Freidlin B; Korn EL; George SL
    Control Clin Trials; 1999 Oct; 20(5):395-407. PubMed ID: 10503800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the Data and Safety Monitoring Board in a clinical trial: the CRISIS study.
    Holubkov R; Casper TC; Dean JM; Anand KJ; Zimmerman J; Meert KL; Newth CJ; Berger J; Harrison R; Willson DF; Nicholson C;
    Pediatr Crit Care Med; 2013 May; 14(4):374-83. PubMed ID: 23392377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory perspectives on data safety monitoring boards: protecting the integrity of data.
    Hemmings R; Day S
    Drug Saf; 2004; 27(1):1-6. PubMed ID: 14720083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of clinical trials and interim analyses from a drug sponsor's point of view.
    Williams GW; Davis RL; Getson AJ; Gould AL; Hwang IK; Matthews H; Shih WJ; Snapinn SM; Walton-Bowen KL
    Stat Med; 1993 Mar; 12(5-6):481-92. PubMed ID: 8493426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 16. The independent statistician model: How well is it working?
    DeMets D
    Clin Trials; 2018 Aug; 15(4):329-334. PubMed ID: 29741390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing trial integrity by protecting the independence of data monitoring committees in clinical trials.
    Fleming TR; Hennekens CH; Pfeffer MA; DeMets DL
    J Biopharm Stat; 2014; 24(5):968-75. PubMed ID: 24926941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data and safety monitoring board deliberations resulting in the early termination of the Monoclonal Antibody Cytomegalovirus Retinitis Trial.
    Gilpin AM; Holbrook JT; Jabs DA; Meinert CL;
    Control Clin Trials; 2003 Feb; 24(1):92-8. PubMed ID: 12559647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia.
    Rufibach K; Heinzmann D; Monnet A
    Pharm Stat; 2020 Jan; 19(1):44-58. PubMed ID: 31461220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the functions and operations of data monitoring committees: Survey and focus group findings.
    Calis KA; Archdeacon P; Bain RP; Forrest A; Perlmutter J; DeMets DL
    Clin Trials; 2017 Feb; 14(1):59-66. PubMed ID: 27885056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.